【レポートの概要（一部）】
1. Report Overview
1.1 Global Dermatological Drugs: Market Overview
1.2 Global Dermatological Drugs Market Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Key Questions Answered By This Analytical Report
1.6 Who Is This Report For?
1.7 Methodology
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Reports
1.10 About Visiongain
2. An Introduction To Dermatological Drugs
2.1 The Pharmaceutical Industry: A Brief Introduction
2.2 An Introduction To Dermatology
2.2.1 The Structural Lay-out Of The Skin, Hair, And Nails
2.2.2 Hair And Nails
2.2.3 Sweat And Sebaceous Glands
2.2.4 Functions Of The Skin
2.3 Common Skin Diseases
2.4 Acne: The Most Common Skin Disease
2.4.1 Acne: Epidemiology
2.4.2 Acne: Causes And Pathogenesis
2.4.3 Acne: Treatment
2.5 Dermatitis: Inflammation Of The Skin
2.5.1 Atopic Dermatitis
2.5.2 Contact Dermatitis
2.5.3 Seborrhoeic Dermatitis
2.5.4 Nummular Dermatitis
2.5.5 Perioral Dermatitis
2.6 Psoriasis: A Complex Multi-factorial Disease
2.7 Rosacea: Vascular Instability
2.8 Alopecia: Excessive Shedding Of Hair
2.9 Skin Infections: A Serious Healthcare Threat
2.9.1 Bacterial Skin Infections
2.9.2 Fungal Skin Infections
2.9.3 Viral Skin Infections
2.10 Common Skin Treatments
2.10.1 Creams and Semisolid Emulsions
2.10.2 Ointments
2.10.3 Lotions
2.10.4 Solutions
2.10.5 Occlusive Therapy
2.10.6 Cleansing Agents
2.10.7 Powders and Hydrophilic Polymer
2.10.8 Anti-Infective Agents
2.10.9 Anti-Inflammatory Agents
2.11 Phases Of Clinical Trials
2.12 Dermatological Drugs: Market Definition In This Report
3. The Global Dermatological Drugs Market, 2015-2025
3.1 The Global Dermatological Drugs Market: Market Overview
3.2 Categorisation Of The Global Dermatological Drugs Market
3.3 The Global Dermatological Drugs Market In 2014
3.4 The Global Dermatological Drugs Market: Market Forecast 2015-2025
3.5 Dermatological Drugs: Changing Market Shares By Sector 2015-2025
4. The Psoriasis Drugs Market: Market Analysis And Forecast 2015-2025
4.1 Psoriasis Treatments: The Dominance Of Biologics
4.1.1 Leading Products In The Psoriasis Drugs Market, 2014
4.2 Psoriasis: Market Trends And Developments, 2015
4.2.1 Biological Drugs In Psoriasis Treatment: A Brief Overview
4.2.2 Issues Around Patent Protection, The Threat Of Biosimilars And Pricing
4.2.3 The Disadvantages Of Biologics In Psoriasis Treatment
4.3 Psoriasis Drugs: Market Forecast 2015-2025
4.3.1 Psoriasis Drugs: Changing Market Shares By Leading Drugs 2015-2025
4.4 Leading Drugs Used In The Treatment Of Psoriasis
4.5 Humira (adalimumab) – AbbVie
4.5.1 Humira: Historical Sales Analysis, 2010-2014
4.5.2 Humira: Sales Forecast 2015-2025
4.5.3 Future Prospects For Biosimilar Versions Of Humira
4.6 Stelara (ustekinumab) – Johnson & Johnson
4.6.1 Stelara: Historical Sales Analysis, 2010-2014
4.6.2 Stelara: Sales Forecast 2015-2025
4.6.3 Intensifying Competition For Stelara
4.7 Enbrel (etanercept) – Amgen/ Pfizer/ Takeda
4.7.1 Enbrel: Co-Promotions And Marketing Rights
4.7.2 Enbrel: Historical Sales Analysis, 2008-2014
4.7.3 Enbrel: Patent Expiries and Potential Competition, 2015-2025
4.7.4 Enbrel: Sales Forecast 2015-2025
4.7.5 Enbrel Auto-injector Pens: A Driver Of Growth In Recent Years
4.7.6 Competition From Other Drugs
4.7.7 Biosimilar Competition For Enbrel
4.8 Remicade (infliximab) – Johnson & Johnson
4.8.1 Remicade: Historical Sales Analysis, 2010-2014
4.8.2 Remicade: Patent Expiries and Potential Competition, 2015-2025
4.8.3 Remicade: Sales Forecast 2015-2025
4.9 Daivobet (betamethasone/calcipotriene) – LEO Pharma
4.9.1 Daivobet: Sales Forecast 2015-2025
4.9.2 LEO Pharma’s Life Cycle Management Of Daivobet
4.9.3 Daivobet/Dovobet/Taclonex – Generic Competition
4.10 Soriatane (acitretin) – GlaxoSmithKline
4.10.1 Soriatane: Sales Forecast 2015-2025
4.11 Other Psoriasis Drugs
4.11.1 Cimzia (certolizumab) – UCB
4.11.2 Cosentyx (secukinumab) – Novartis
4.11.3 Otezla (apremilast) – Celgene
4.11.4 Sorilux (calcipotriene foam) – GSK
4.11.5 Other Psoriasis Drugs: Sales Forecast 2015-2025
4.12 Psoriasis Drugs Market: Summary
5. Skin Infection Drugs Market: Market Analysis And Forecast 2015-2025
5.1 Skin Infection Drugs: Abundant Growth Opportunities
5.1.1 Leading Products In The Skin Infection Drugs Market, 2014
5.2 Skin Infection Drugs: Market Forecast 2015-2025
5.2.1 Skin Infection Drugs: Changing Market Shares By Leading Drugs 2015-2025
5.3 Leading Drugs Used In The Treatment Of Skin Infections
5.4 Cubicin (daptomycin) – Cubist Pharmaceuticals/ Merck & Co
5.4.1 Acquisition By Merck & Co
5.4.2 Generic Competition For Cubicin
5.4.3 Cubicin: Sales Forecast 2015-2025
5.4.4 Lifecycle Management Strategies For Cubicin
5.5 Zyvox (linezolid) – Pfizer
5.5.1 Zyvox: Historical Sales Analysis, 2010-2014
5.5.2 Zyvox: Sales Forecast 2015-2025
5.5.3 The Threats To Zyvox Sales From Competing New Drugs
5.6 Valtrex (valaciclovir) – GSK
5.6.1 Valtrex: Historical Sales Analysis, 2010-2014
5.6.2 Valtrex: Sales Forecast 2015-2025
5.7 Canesten (clotrimazole) – Bayer
5.7.1 Canesten: Historical Sales Analysis, 2011-2014
5.7.2 Canesten: Sales Forecast 2015-2025
5.8 Lamisil (terbinafine) – Novartis
5.8.1 Lamisil Patent Expiry
5.8.2 Lamisil Sales Affected By Novartis Manufacturing Problems
5.8.3 Lamisil: Sales Forecast 2015-2025
5.9 Bactroban (mupirocin) – GSK
5.9.1 Bactroban: Historical Sales Analysis, 2010-2013
5.9.2 Bactroban: Sales Forecast 2015-2025
5.10 Other Skin Infection Drugs
5.10.1 Dalvance (dalbavancin) – Durata Therapeutics
5.10.2 Jublia (efinaconazole) – Valeant
5.10.3 Kerydin (tavaborole) – Anacor
5.10.4 Sivextro (tedizolid) – Cubist Pharmaceuticals
5.10.5 Zovirax (acyclovir) – Valeant/GSK
5.10.5.1 Valeant Acquires Zovirax In US And Canada
5.10.5.2 Mylan’s Generic Zovirax And Actavis’ Authorised Generic
5.10.6 Other Skin Infection Drugs: Sales Forecast 2015-2025
5.11 Skin Infection Drugs: Market Summary
6. Acne Drugs Market: Market Analysis And Forecast 2015-2025
6.1 Acne Drugs: A Diversified Market
6.1.1 Leading Products In The Acne Drugs Market, 2014
6.2 Acne Drugs Market: Recent Trends and Developments
6.2.1 The Rise Of Combination Therapies In Acne Treatment
6.2.2 Oral Contraceptives In Treating Acne
6.2.3 The Threat Of Generic Competition In The Acne Drugs Market
6.3 Acne Drugs: Market Forecast 2015-2025
6.3.1 Acne Drugs: Changing Market Shares By Leading Drugs 2015-2025
6.4 Leading Drugs In The Acne Drugs Market
6.5 Solodyn (minocycline) – Valeant
6.5.1 Solodyn: Sales Forecast 2015-2025
6.5.2 Antitrust Action Over Solodyn Pay-For-Delay Deals
6.5.3 Impax And Medicis Collaborating On Advanced Solodyn
6.5.4 Medicis And Lupin Settle
6.6 Epiduo (adapalene/benzoyl peroxide) – Galderma/ Nestlé Skin Health
6.6.1 Epiduo: Sales Forecast 2015-2025
6.6.2 Galderma Settlement Agreement Over Generic Epiduo
6.6.3 Paediatric Approval For Epiduo
6.7 Claravis (isotretinoin) – Teva
6.7.1 Claravis: Sales Forecast 2015-2025
6.8 Aczone (dapsone) – Allergan
6.8.1 Aczone: Sales Forecast 2015-2025
6.9 Differin (adapalene) – Galderma/ Nestlé Skin Health
6.9.1 Recent Generic Competition To Differin
6.9.2 Differin: Sales Forecast 2015-2025
6.9.3 Federal Circuit Court Invalidates Differin Patents
6.10 Absorica/Epuris (CIP-isotretinoin) – Cipher/ Sun Pharma
6.10.1 Absorica/Epuris: Sales Forecast 2015-2025
6.11 Ziana (clindamycin/tretinoin) – Valeant Pharmaceuticals International
6.11.1 Valeant’s Patent Settlement With Actavis Over Ziana
6.11.2 Ziana: Sales Forecast 2015-2025
6.12 Doryx (doxycycline) – Actavis/ Mayne Pharma
6.12.1 Lifecycle Management Strategies For Doryx
6.12.2 Divestment Agreement With Mayne Pharma
6.12.3 Generic Competition For Doryx
6.12.4 Doryx: Sales Forecast 2015-2025
6.13 Other Acne Drugs
6.13.1 Acanya (clindamycin/benzoyl peroxide) – Dow / Valeant
6.13.1.1 Acanya: Financial Analysis
6.13.1.2 Actavis Claims First-to-File Exclusivity for its Acanya ANDA
6.13.1.3 Legal Battles Involving Dow/Valeant, Perrigo, And Watson
6.13.2 Amnesteem (isotretinoin) – Mylan
6.13.2.1 Amnesteem: Financial Analysis
6.13.3 Diane (cyproterone/ethinyl estradiol) – Bayer
6.13.4 Duac (clindamycin/benzoyl peroxide) – GlaxoSmithKline
6.13.4.1 Duac: Financial Analysis
6.13.5 Veltin (tretinoin/clindamycin) – GSK
6.13.6 Other Acne Drugs: Sales Forecast 2015-2025
6.14 Acne Drugs: Market Summary
7. Dermatitis Drugs Market: Market Analysis And Forecast 2015-2025
7.1 Dermatitis Drugs: High Generic Penetration
7.1.1 Leading Products In The Dermatitis Drugs Market, 2014
7.2 Dermatitis Drugs: Market Forecast 2015-2025
7.2.1 Dermatitis Drugs: Changing Market Shares By Leading Drugs 2015-2025
7.3 Leading Drugs In The Dermatitis Drugs Market
7.4 Bepanthen (dexpanthenol)/ Bepanthol – Bayer
7.4.1 Bepanthen: Sales Forecast 2015-2025
7.5 Protopic (tacrolimus) – Astellas Pharma/ Roche
7.5.1 Protopic Benefits From Expanded Indication
7.5.2 Generic Competition For Protopic
7.5.3 Protopic: Sales Forecast 2015-2025
7.6 Elidel (pimecrolimus) – Meda Pharma/ Valeant
7.6.1 Elidel: Sales Forecast 2015-2025
7.7 Elocon (mometasone) – Merck & Co
7.7.1 Elocon: Sales Forecast 2015-2025
7.8 Other Dermatitis Drugs: Sales Forecast 2015-2025
7.9 Dermatitis Drugs: Market Outlook
8. Leading National Markets For Dermatological Drugs, 2015-2025
8.1 The Dermatological Drugs Market By Region
8.1.1 The Global Distribution Of Dermatological Drugs In 2014
8.2 Leading National Markets: Forecast 2015-2025
8.2.1 Changing Market Shares By Region, 2015-2025
8.3 Regional Dermatological Drugs Markets: Analysis And Forecasts, 2015-2025
8.4 United States: The Largest Dermatological Drugs Market
8.4.1 The Impact Of An Expanding Medicare Coverage
8.4.2 Legislative Environment Stimulating Biosimilars Market?
8.4.3 US Dermatological Drugs Market: Market Forecast 2015-2025
8.5 The EU5 Markets: Growth Expected In Each Country
8.5.1 EU5 Dermatological Drugs Market: Market Forecast 2015-2025
8.5.1.1 EU5 Markets: Changing Market Shares By Country, 2015-2025
8.5.2 Germany
8.5.2.1 German Dermatological Drugs Market: Market Forecast 2015-2025
8.5.3 France
8.5.3.1 French Dermatological Drugs Market Forecast 2015-2025
8.5.4 UK
8.5.4.1 UK Dermatological Drugs Market Forecast 2015-2025
8.5.5 Italy
8.5.5.1 Italian Dermatological Drugs Market Forecast 2015-2025
8.5.6 Spain
8.5.6.1 Spanish Dermatological Drugs Market Forecast 2015-2025
8.6 Japan
8.6.1 The Cost Of Treatment In Japan
8.6.2 Japanese Pharmaceutical Industry Regulatory Reform
8.6.3 Japanese Dermatological Drugs Market Forecast 2015-2025
8.7 China
8.7.1 Expansion Of Healthcare Coverage And Reimbursement In China
8.7.2 Improving Public Perception Of Dermatology In China
8.7.3 Price Controls And The Anhui Model
8.7.4 Chinese Dermatological Drugs Market Forecast 2015-2025
8.8 India
8.8.1 The Effects Of The Drug Prices Control Order Of 2013
8.8.2 India’s Expansion Of Healthcare Provision
8.8.3 Indian Dermatological Drugs Market Forecast 2015-2025
8.9 Brazil
8.9.1 The Growth In Brazil’s Healthcare Landscape
8.9.2 Clearer Access To Medicines In Brazil
8.9.3 Brazilian Dermatological Drugs Market Forecast 2015-2025
8.10 Russia
8.10.1 Pharma2020 Strategy – Healthcare And Industry Reform
8.10.2 Russian Dermatological Drugs Market Forecast 2015-2025
8.11 Mexico
8.11.1 Seguro Popular: Mexican Healthcare Reform
8.11.2 Are Multinationals Waking Up To Mexico’s Potential?
8.11.3 Mexican Dermatological Drugs Market Forecast 2015-2025
8.12 Rest of the World
8.12.1 The Rest of the World Dermatological Drugs Market Forecast 2015-2025
9. Leading Companies In The Dermatological Drugs Market, 2015-2025
9.1 Dermatological Drugs – A Rapidly Consolidating Market
9.2 Galderma (Nestle Skin Health S.A.)
9.2.1 Galderma: Dermatological Drugs Portfolio, 2015
9.2.2 Galderma: Recent Developments
9.2.2.1 Nestlé’s Acquisition Of Galderma
9.2.2.2 Approval Of Soolantra For Rosacea
9.2.2.3 Mirvaso Launched For Rosacea
9.3 Johnson & Johnson
9.3.1 Johnson & Johnson: Dermatological Drugs Portfolio, 2015
9.3.2 Johnson & Johnson Dermatological Drugs Sales Forecast 2015-2025
9.3.3 Johnson And Johnson: Dermatological Drug Development Efforts, 2015
9.4 AbbVie
9.4.1 AbbVie: Dermatological Drugs Portfolio, 2015
9.4.2 AbbVie Dermatological Drugs Sales Forecast 2015-2025
9.4.3 AbbVie: Dermatological Drugs Development Pipeline, 2015
9.4.3.1 BT-061 (tregalizumab) For The Treatment Of Psoriasis
9.5 GlaxoSmithKline (GSK)
9.5.1 GSK: Dermatological Drugs Portfolio, 2015
9.5.2 GlaxoSmithKline (GSK) Dermatological Drugs Sales Forecast 2015-2025
9.5.3 GlaxoSmithKline (GSK): Recent Developments
9.5.3.1 Business Restructuring Arrangements With Novartis
9.5.3.2 Tafinlar and Mekinist Combination Approved by FDA, Withdrawn in EU
9.5.4 GlaxoSmithKline (GSK): Dermatological Drugs Development Pipeline, 2015
9.6 Pfizer
9.6.1 Pfizer: Dermatological Drugs Portfolio, 2015
9.6.2 Pfizer Dermatological Drugs Sales Forecast 2015-2025
9.6.3 Pfizer: Dermatological Drugs Development Pipeline, 2015
9.7 LEO Pharma
9.7.1 LEO Pharma: Dermatological Drugs Portfolio, 2015
9.7.2 LEO Pharma Dermatological Drugs Sales Forecast 2015-2025
10. Dermatological Drugs: Research And Development Pipeline, 2015-2025
10.1 Innovative Products Currently In Development Will Drive Growth
10.1.1 New Technology In R&D Pipeline Activities
10.1.1.1 Reformulation
10.1.1.2 Combination Treatments
10.1.1.3 New Mechanisms And Drug Delivery Technologies
10.1.1.4 Potential Market Entrants
10.2 Psoriasis Drugs Development Pipeline, 2015
10.2.1 Psoriasis Drugs In Phase 3 Development
10.2.1.1 000-0551 Lotion (halobetasol) – Therapeutics, Inc
10.2.1.2 AMG 827 (brodalumab) – AstraZeneca/ Amgen
10.2.1.3 CF101 (IB-MECA) – Can-Fite BioPharma
10.2.1.4 CNTO 1959 (guselkumab) – MorphoSys/ Janssen
10.2.1.5 LAS41008 (dimethyl fumarate) – Almirall
10.2.1.6 LEO 90100 – LEO Pharma
10.2.1.7 LY2439821 (ixekizumab) – Eli Lilly
10.2.1.8 MK-3222/SCH 900222 (tildrakizumab) – Merck
10.2.1.9 STF 115469 (calcipotriene foam) – GSK
10.2.1.10 Xeljanz (tofacitinib) – Pfizer
10.2.2 Psoriasis Drugs In Phase 2 Development
10.2.2.1 AN2728 (PDE-4 inhibitor) – Anacor Pharmaceuticals
10.2.2.2 CT327 (TrkA inhibitor) – Creabilis Therapeutics
10.2.2.3 ASP015K (JAK inhibitor) – Astellas Pharma
10.2.2.4 Jakavi/Jakafi (ruxolitinib) – Incyte/ Novartis
10.2.2.5 LY3009104 (baricitinib) – Incyte/ Eli Lilly
10.2.2.6 PH-10 (Rose Bengal) – Provectus Biopharmaceuticals
10.2.3 Psoriasis Drugs In Phase 1 And Pre-clinical Development
10.3 Skin Infection Drugs Development Pipeline, 2015
10.3.1 Drugs In Phase 3 Development For Skin Infections
10.3.1.1 Delafloxacin (delafloxacin) – Melinta Pharmaceuticals
10.3.1.2 NB-001 – NanoBio Corporation
10.3.1.3 Orbactiv/ Nuvocid (oritavancin) – The Medicines Company
10.3.1.4 Luliconazole – Topica Pharmaceuticals
10.3.2 Drugs In Phase 2 Development For Skin Infections
10.3.3 Drugs In Phase 1 And Preclinical Pipeline For Skin Infections
10.4 Acne Drugs Development Pipeline, 2015
10.4.1 Drugs In Phase 3 Development For Acne
10.4.1.1 Duac low dose (clindamycin/ benzoyl peroxide) – GlaxoSmithKline
10.4.1.2 Visonac (photodynamic therapy) – Photocure
10.4.2 Drugs In Phase 2 Development For Acne
10.4.3 Drugs In Phase 1 And Pre-clinical Development For Acne
10.4.4 A Possible Vaccine For Acne
10.5 Dermatitis Drugs Development Pipeline, 2015
10.5.1 Drugs In Phase 3 Development For Dermatitis
10.5.1.1 Toctino (alitretinoin) – GSK
10.5.1.2 Dermadexin and Pruridexin (P3CGM) – Cipher Pharmaceuticals
10.5.1.3 Dexeryl Cream (glycerol/paraffin emollient) – Pierre Fabre
10.5.1.4 REGN668/SAR231893 (dupilumab) – Regeneron/ Sanofi
10.5.1.5 Soriatane (acitretin) – InnovaDerm/Tribute Pharmaceuticals
10.5.2 Drugs In Phase 2 Development For Dermatitis
10.5.3 Drugs In Phase 1 And Preclinical Stages Of Development For Dermatitis
10.6 Other Dermatological Drugs Development Pipeline, 2015
10.6.1 Other Dermatological Drugs: Filed or Recently Launched
10.6.1.1 Actikerall (fluorouracil/salicylic acid) – Almirall
10.6.1.2 Ameluz (5-ALA photodynamic therapy) – Biofrontera
10.6.1.3 Keytruda (MK-3475, Pembrolizumab) – Merck
10.6.1.4 Mirvaso (brimonidine) – Galderma
10.6.1.5 Picato (ingenol mebutate) – LEO Pharma
10.6.1.6 Xolair (omalizumab) – Novartis/ Roche
10.6.2 Other Dermatological Drugs: Phase 3 Pipeline Products, 2015
10.6.2.1 Atralin (tretinoin) – Valeant
10.6.2.2 BMS-936558 (nivolumab) – Bristol-Myers Squibb
10.6.2.3 CD5024 (ivermectin) – Galderma
10.6.2.4 Latisse (bimatoprost) – Allergan (Actavis)
10.6.2.5 LEE011, LGX818, and MEK162 – Novartis
10.6.2.6 Oleogel-S10 (triterpene extract) – Birken AG
10.6.2.7 PV-10 (Rose Bengal) – Provectus Pharmaceuticals
10.6.2.8 SR-T100 gel (Solanum incanum extract) – G&E Herbal Biotechnology
10.6.2.9 TVEC (talimogene laherparepvec) – Amgen
10.6.3 Other Dermatological Drugs: Phase 2 Pipeline Products, 2015
10.6.4 Other Dermatological Drugs: Phase 1 and Preclinical Pipeline
11. Qualitative Analysis Of The Dermatological Drugs Market, 2015-2025
11.1 Market Factors Influencing Dermatological Drugs
11.2 SWOT Analysis Of The Global Dermatological Drugs Market, 2015-2025
11.2.1 Strengths
11.2.1.1 The High Unmet Clinical Need In Dermatology
11.2.1.2 A Healthy Pipeline Of Development-Stage Products
11.2.1.3 Strong Industry-Physician Relationships
11.2.2 Weaknesses
11.2.2.1 Limited Efficacy And Adverse Effects May Impact Product Uptake
11.2.2.2 Patient Adherence – A Major Challenge To Treatment Design
11.2.2.3 Impending Patent Expiries And The Challenges Posed By Generic Competition
11.2.3 Opportunities
11.2.3.1 The High-Growth Sectors In Dermatology
11.2.3.2 Personalised Dermatology: Technological Advances In Genomics
11.2.3.3 Advances In Topical Drug Delivery Methods Offers Product Differentiation
11.2.3.4 Consolidation Within Dermatology – Opportunity For Synergistic Growth?
11.2.4 Threats
11.2.4.1 Uncertain Surrounding Reimbursement And Payment Approvals
11.2.4.2 The Rising Cost Of Research And Development
11.2.4.3 Downward Pressures On Drug Prices
11.3 Porter’s Five Force Analysis Of The Global Dermatological Drugs Market, 2015-2025
11.3.1 Threat Of New Entrants
11.3.2 Threat Of Substitutes
11.3.3 Rivalry Among Competitors
11.3.4 Power Of Buyers
11.3.5 Power Of Suppliers
12. Expert Opinions from Our Primary Research
12.1 Interview With Kathleen Deardorff, Chief Operating Officer At Photocure ASA
12.1.1 Visonac As An Innovative First-In-Class Treatment
12.1.2 Photocure’s Development Plans For Visonac
12.1.3 Commercialisation Strategy For Visonac
12.1.4 On The Geographical Reach Of Acne Treatments
12.1.5 The Key Unmet Needs Within Patient Populations For Acne
12.1.6 The Key Forces Driving And Restraining The Development Of Acne Therapies
12.1.7 On The Current Development Pipeline For Acne Therapies
12.1.8 On Photocure’s Plans For Future Growth
12.1.9 Future Prospects For The Acne Treatments Market
13. Conclusions
13.1 Overview Of Current Market Conditions And Market Forecast, 2014-2025
13.2 Leading Sectors In Dermatological Drugs In 2014
13.3 Leading Regions In The Dermatological Drugs Market In 2014
13.4 Future Outlook For The Various Sectors Within The Dermatological Drugs Market, 2015-2025
13.5 What Does The Future Hold For Dermatological Drugs?
【レポート販売概要】
■ タイトル：皮膚科用薬剤の世界市場：皮膚感染症薬、皮膚炎薬、にきび薬、乾癬薬■ 英文：Dermatological Drugs Market Forecast 2015-2025 : Opportunities for Leading Companies
■ 発行日：2015年5月
■ 調査会社：visiongain
■ 商品コード：VGAIN5052605
■ 調査対象地域：グローバル
- 医療エレクトロニクスの世界市場予測（～2022年）：センサー、電池、メモリ機器、ディスプレイ装置、マイクロコントローラーThe medical electronics market was valued at USD 3.01 Billion in 2015 and is expected to reach USD 4.41 Billion by 2022, growing at a CAGR of 5.4% between 2016 and 2022. Factors such as rising ageing population and growing lifestyle diseases; rising demand for personalized, easy to use, and advanced healthcare devices; and increasing adoption of wearable electronics are driving the growth of this …
- 世界の建設重機市場：土工機械、マテリアルハンドリング装置、大型建設車両Heavy construction equipment is a critical tool for construction activities. They form the backbone of any construction project by reducing human effort and time. Heavy construction equipment has contributed to the rapid development of infrastructure for the development of economies globally. Heavy construction equipment comes in different types that include Earth moving equipment (Excavators, Loa …
- フッ素系界面活性剤の世界市場：種類、用途、地域別市場分析The fluorosurfactants market size in terms of value is projected to grow at a CAGR of 5.1% between 2014 and 2019 to reach $364.1 million by 2019. North America held the largest share in fluorosurfactants market in 2013. Asia-Pacific is projected to register highest growth driven by the increasing consumptions of paint and coatings in architectural and automotive industries. Demand for paint and co …
- シリコーンの世界市場予測（～2022年）：エラストマー、液体、樹脂、ゲルThe global silicone market is estimated at USD 14.20 Billion in 2017 and is projected to reach USD 18.87 Billion by 2022, at a CAGR of 5.85% between 2017 and 2022. The market is witnessing growth due to the efficient and sustainable properties of silicone which makes it suitable for use in various end-use industries and growing demand for silicone in emerging clusters of Asia Pacific and the Middl …
- 移動体通信事業者（MNO）のM2M戦略（Mobile Network Operator Machine-to-Machine (M2M) Strategies）Machine to Machine (M2M) is unleashing a wave of new possibilities for data gathering, predictive analytics and automation. M2M can be employed in various mundane yet important tasks in virtually every industry/segment including healthcare, telematics, asset management, surveillance, power grid, connected home, connected car and much more. M2M services are a key part of every successful enterprise …
- 生体触媒作用・生体触媒の世界市場2016-2020About Biocatalysis and Biocatalysts Biocatalysis is a chemical process in which enzymes and other biological catalysts are used to speed up the reaction between organic components. These enzymes are derived from microorganisms or plant and animal cells. The use and penetration of biocatalysts are increasing in industries, such as agriculture and feed, textile, biofuel production, and biopharmaceut …
- セーフティレーザースキャナーの世界市場予測（～2023年）“SAFETY LASER SCANNER MARKET TO GROW AT A HIGHER CAGR of 5.99% DURING 2018–2023”The overall safety laser scanner market is expected to grow from USD 304 million in 2018 to USD 406 million by 2023, at a high CAGR during the forecast period. Safety laser scanners offer long-term cost-effective solutions for use with new machine installations or for retrofitting machines, plants, or even vehicles. Th …
- アジア太平洋のパッケージ変電所市場予測（～2020）The Asia-Pacific package substation market is expected to reach USD 3.04 Billion by 2020, at a CAGR of 7.82% from 2015 to 2020. The growth of this market is attributed to huge electricity demand and modernization of existing power infrastructure in developing countries. Investments for renewable power generation in South Asian countries have been planned to meet the rising power demand, which in t …
- アメリカの感染症検査市場：分子診断検査、POC検査、免疫診断検査About infectious disease testing Infectious diseases are caused by microorganisms such as viruses, bacteria, fungi, and parasites. Infectious diseases are one of the primary contributors to morbidity and mortality worldwide. According to the CDC, in the US there are more than 1.2 million people living with HIV infection and one in eight are unaware about their condition. In 2013, it was estimated …
- キレート剤の世界市場2016-2020About the Chelating Agents Market Chelating agents, also called chelants, sequestering agents, or complexing agents, form stable complexes after mixing with metal ions. These compounds achieve this by synchronizing with the metal ions of at least two sites, inactivating and solubilizing the metal ions that would otherwise damage the system on which they have been used. Chelating agents are primari …
- 粒度分布測定装置の世界市場2016-2020About Particle Size Analyzer Particle size analysis is a technique that helps in determining the size of particles present in materials such as liquid and powder. The functionality of the material is critical to the size of the particle, and therefore thorough characterization of the material must be carried out. This analysis is largely carried out by players in industries such as healthcare, min …
- 世界の繊維化学薬品市場（2014-2018）TechNavio's analysts forecast the Global Textile Chemicals market to grow at a CAGR of 3.60 percent over the period 2013-2018. One of the key factors contributing to this market growth is the increased demand for finishing chemicals. The Global Textile Chemicals market has also been witnessing the development of eco-friendly products and bio-auxiliaries. However, the rising environmental concerns …
- 携帯電話用ケース及び機構部品製造の世界市場2015-2019About Mobile Phone Cases and Structural Parts Mobile phone cases and structural parts are the essential components of a mobile phone. Mobile phone manufacturers attach a high significance to the casing, as it forms an important factor for product differentiation and unique selling point. Consumers over the years have been looking at personalizing their mobile phones through different phone cases. …
- スタジアム照明の世界市場予測（～2023年）“Enhancing stadium experiences of fans using LEDs to drive growth of stadium lighting market”The stadium lighting market is expected to reach USD 622.2 million by 2023 from USD 432.0 million in 2018, at a CAGR of 7.57% between 2018 and 2023. Factors such as upcoming national and international sports events, enhanced stadium experiences of fans using LEDs, and reducing costs of LEDs and lifecycle o …
- プラダー･ウィリ症候群(Prader-Willi Syndrome (PWS))の治療薬パイプライン動向（2015年上半期版）Prader-Willi Syndrome (PWS) - Pipeline Review, H1 2015 Summary Global Markets Direct’s, ‘Prader-Willi Syndrome (PWS) - Pipeline Review, H1 2015’, provides an overview of the Prader-Willi Syndrome (PWS)’s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Prader-Willi Syndrome (PWS), complete with comparative analysis at various stages, therapeut …
